Comparing everolimus‐based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from 6 months after heart transplantation: The randomized MANDELA study-Reference-Cited by-同舟云学术

Comparing everolimus‐based immunosuppression with reduction or withdrawal of calcineurin inhibitor reduction from 6 months after heart transplantation: The randomized MANDELA study

Published:2019-04-05 Issue:11 Volume:19 Page:3006-3017
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Barten Markus J.¹,Hirt Stephan W.²,Garbade Jens³,Bara Christoph⁴,Doesch Andreas O.⁵,Knosalla Christoph⁶,Grinninger Carola⁷,Stypmann Jörg⁸,Sieder Christian⁹,Lehmkuhl Hans B.⁶,Porstner Martina⁹,Schulz Uwe¹⁰,Deuse Tobias,Costard‐Jaeckle Angelika,Sill Björn,Haneya Assad,Eifert Sandra,Kaczmarek Ingo,Eickmeyer Holm,Hiemann Nicola,Kemper Dagmar

Affiliation:

1. Department of Cardiovascular Surgery University Heart Center Hamburg Hamburg Germany

2. Department of Cardiothoracic Surgery University Hospital Regensburg Regensburg Germany

3. University Department of Cardiac Surgery Leipzig Heart Center Leipzig Germany

4. Division of Cardiovascular Thoracic and Transplantation Surgery Hannover Medical School Hannover Germany

5. Department of Cardiology University Hospital Heidelberg Heidelberg Germany

6. Department of Cardiothoracic and Vascular Surgery German Heart Institute Berlin DZHK (German Centre for Cardiovascular Research), partner site Berlin Berlin Germany

7. Department of Cardiac Surgery Munich Transplantation Center Klinikum Großhadern LMU Munich Germany

8. Department of Cardiovascular Medicine Division of Cardiology University Hospital Münster Münster Germany

9. Novartis Pharma GmbH Nuremberg Germany

10. Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW Ruhr University Bochum Bad Oeynhausen Germany

Funder

Novartis Pharma

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajt.15361

Reference26 articles.

1. Renal protection strategies after heart transplantation

2. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report—2017; Focus Theme: Allograft ischemic time

3. Mechanism of action of the immunosuppressant rapamycin

4. A Comprehensive Review of Everolimus Clinical Reports

5. Everolimus Versus Mycophenolate Mofetil in Heart Transplantation: A Randomized, Multicenter Trial

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increase of Cardiac Autoantibodies Against Beta-2-adrenergic Receptor During Acute Cellular Heart Transplant Rejection;Transplantation;2024-05-21

2. Impact of Everolimus Initiation and Corticosteroid Weaning During Acute Phase After Heart Transplantation on Clinical Outcome: Data from the Korean Organ Transplant Registry (KOTRY);Transplant International;2024-04-05

3. Pharmacotherapy in the heart transplant recipient: A primer for nurse clinicians and pharmacists;Clinical Transplantation;2024-02

4. Heart Transplantation;Journal of Clinical Medicine;2024-01-18

5. Miscellaneous Adverse Events and Causes of Death;Textbook of Transplantation and Mechanical Support for End‐Stage Heart and Lung Disease;2023-09-08